2024 年度独立董事述职报告（王焕军） 深圳市海王生物工程股份有限公司 2024年度独立董事述职报告（王焕军） 作为深圳市海王生物工程股份有限公司（以下简称"公司"）的独立董事，在 2024年度，本人严格按照《公司法》《上市公司独立董事管理办法》《公司章程》 《独立董事工作制度》等相关规定，恪尽职守、勤勉尽责，积极出席相关会议， 认真审议董事局各项议案，全面关注公司的发展状况，切实维护了公司和股东， 尤其是中小股东的利益。现将2024年度本人履行独立董事职责的情况汇报如下： 一、独立董事基本情况 王焕军，男，1977年1月出生，中共党员，无境外永久居留权，南开大学经 济学硕士，拥有高级会计师职称、中国注册会计师、注册税务师等专业资格。曾 任天健会计师事务所部门经理助理，现任中兴财光华会计师事务所(特殊普通合 伙)合伙人、浙江分所负责人，兼任浙江争光实业股份有限公司非独立董事、灵 幻企业管理咨询(杭州)有限公司监事等职，2022年10月起任公司独立董事。 本人任职情况符合相关法律法规和公司内部制度中对独立董事独立性的要 求。在2024年度任职期间恪尽职守，忠实履职，本人未在公司担任除独立董事以 外的任何职务； ...

2024 年度独立董事述职报告（张巍松） 深圳市海王生物工程股份有限公司 2024年度独立董事述职报告（张巍松） 作为深圳市海王生物工程股份有限公司（以下简称"公司"）的独立董事，在 2024年度，本人严格按照《公司法》《上市公司独立董事管理办法》《公司章程》 《独立董事工作制度》等相关规定，恪尽职守、勤勉尽责，积极出席相关会议， 认真审议董事局各项议案，全面关注公司的发展状况，切实维护了公司和股东， 尤其是中小股东的利益。现将2024年度本人履行独立董事职责的情况汇报如下： 一、独立董事基本情况 张巍松，男，1973年12月出生，无境外永久居留权，深圳大学法学学士，执 业律师。2010年至2023年11月在广东星辰律师事务所任高级合伙人，2023年11 月至今在北京浩天（深圳）律师事务所任高级合伙人。现任公司独立董事。 本人任职情况符合相关法律法规和公司内部制度中对独立董事独立性的要 求。在2024年度任职期间恪尽职守，忠实履职，本人未在公司担任除独立董事以 外的任何职务；本人及主要亲属均不属于公司主要股东，均未在公司主要股东及 其附属单位担任任何职务；不属于与本公司及控股股东、实际控制人或其附属企 业有重 ...

Financial Performance - The company's revenue for Q1 2025 was ¥7,375,593,948.22, representing a decrease of 8.81% compared to ¥8,087,937,989.71 in the same period last year[5] - Net profit attributable to shareholders was ¥23,715,783.03, down 44.38% from ¥42,641,426.53 year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥74,743,595.07, a decline of 257.78% compared to ¥47,372,296.28 in the previous year[5] - Basic and diluted earnings per share were both ¥0.0090, down 44.44% from ¥0.0162 year-on-year[5] - Total operating revenue for the current period is ¥7,375,593,948.22, a decrease of 8.8% from ¥8,087,937,989.71 in the previous period[17] - Net profit for the current period is ¥52,955,598.60, down 23.5% from ¥69,171,556.13 in the previous period[18] - Total comprehensive income for the period was CNY 52,955,598.60, a decrease from CNY 69,171,556.13 in the previous period[19] - Net income attributable to the parent company was CNY 23,715,783.03, down from CNY 42,641,426.53 year-over-year[19] Cash Flow and Assets - The company's cash flow from operating activities was ¥47,431,311.19, a decrease of 16.43% from ¥56,755,485.31 in the same period last year[5] - Cash inflows from operating activities totaled CNY 8,409,891,136.83, a decline from CNY 9,411,431,958.97[19] - Cash outflows from operating activities were CNY 8,362,459,825.64, compared to CNY 9,354,676,473.66 in the previous period[19] - Net cash flow from operating activities was CNY 47,431,311.19, down from CNY 56,755,485.31[19] - Cash and cash equivalents decreased to CNY 3,275,636,071.84 from CNY 3,456,273,633.71[14] - The ending balance of cash and cash equivalents was CNY 984,880,498.93, down from CNY 1,102,450,212.12[20] - The company reported a total current assets of CNY 25,757,120,262.87, a slight decrease from CNY 25,834,823,219.04 at the beginning of the period[14] - The company's total assets amount to ¥28,603,975,902.91, slightly down from ¥28,798,320,164.17[16] - Total liabilities decreased to ¥25,674,501,567.09 from ¥25,954,556,650.61, a reduction of 1.1%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 126,898[10] - The controlling shareholder changed to Silk Spun Group, which now holds 12% of the company's shares[12] - The company has a total of 1,216,445,128 shares held by Shenzhen Haiwang Group, the largest shareholder[11] Strategic Initiatives - The company plans to issue up to 620,000,000 shares to specific investors, pending regulatory approval[13] - The company signed a cooperation agreement with Silk Spun Group, indicating potential strategic partnerships[12] - The company plans to focus on market expansion and new product development in the upcoming quarters[18] Non-Recurring Items and Investments - Non-recurring gains and losses totaled ¥98,459,378.10, primarily from the disposal of subsidiaries[6] - Investment income increased by 1290.07% year-on-year, mainly due to gains from the disposal of subsidiaries[8] - The company's long-term equity investments remained stable at CNY 193,571,404.87[14] - The company reported an investment income of ¥95,295,953.60, compared to a loss of ¥8,007,570.45 in the previous period[17] Operating Costs and Expenses - Total operating costs decreased to ¥7,352,946,262.98 from ¥7,981,269,889.39, reflecting a reduction of 7.8%[17] - Research and development expenses increased to ¥11,250,327.04 from ¥10,122,756.35, indicating a rise of 11.2%[17] Audit and Compliance - The first quarter report was not audited[21] - The company is committed to timely information disclosure regarding major events as per regulatory requirements[13]

Financial Performance - The company's operating revenue for 2024 was ¥30.32 billion, a decrease of 16.75% compared to ¥36.42 billion in 2023[6]. - The net profit attributable to shareholders was -¥1.19 billion, an improvement of 29.38% from -¥1.69 billion in the previous year[6]. - The cash flow from operating activities showed a significant increase, reaching ¥39.54 million, compared to -¥410.19 million in 2023, marking a 109.64% improvement[6]. - The total assets at the end of 2024 were ¥28.80 billion, down 10.85% from ¥32.30 billion at the end of 2023[6]. - The net assets attributable to shareholders decreased by 40.22% to ¥1.80 billion from ¥3.00 billion in 2023[6]. - The company reported a basic and diluted earnings per share of -¥0.4536, an improvement of 29.38% from -¥0.6423 in 2023[6]. - The company reported a net profit attributable to shareholders of approximately CNY -1.193 billion, mainly due to significant goodwill and accounts receivable impairments[43]. - The total operating revenue for 2024 was approximately ¥30.32 billion, a decrease of 16.75% compared to ¥36.42 billion in 2023[71]. - The pharmaceutical commercial circulation segment generated ¥20.06 billion, accounting for 66.15% of total revenue, down 14.89% from ¥23.57 billion in 2023[71]. - The medical device segment reported revenue of ¥9.59 billion, representing 31.63% of total revenue, a decline of 21.27% from ¥12.18 billion in 2023[71]. Business Strategy and Development - The company is focusing on cost control and efficiency improvements in response to ongoing price pressures in the pharmaceutical market[31]. - The company aims to enhance its medical device business through the establishment of Haiwang Medical Technology Co., Ltd., focusing on resource integration and business line expansion[47]. - The company is actively exploring business model upgrades through digitalization and supply chain value-added services to enhance customer loyalty[48]. - The company aims to integrate and upgrade medical device resources, focusing on domestic substitution and full industry chain layout, leveraging partnerships with international giants like Boston Scientific and Johnson & Johnson[102]. - The company is accelerating the transformation towards a "research-manufacturing-sales" full industry chain model, enhancing supply chain localization and product quality[103]. - The company plans to optimize its pharmaceutical distribution business by reducing low-margin drug operations and shifting resources towards high-margin medical device sales, targeting a steady growth in traditional quality business while eliminating ineffective operations[112]. - The company intends to accelerate the integration of its medical device business across various regions, enhancing overall coordination and competitiveness in the market[113]. Research and Development - The R&D team consists of 228 members, having completed over 30 postdoctoral research projects, focusing on major diseases such as cancer and cardiovascular diseases[55]. - The company has 25 invention patents and has passed consistency evaluations for 5 generic drug varieties, with ongoing evaluations for multiple other products[52]. - The company completed high-dose pharmacokinetic testing for HW130, a drug for chemotherapy enhancement, which is expected to reduce clinical development risks[83]. - The company is advancing its innovative drug development, with significant progress in clinical trials for projects like NEP018 and HW130, and is actively pursuing patent applications[109]. Governance and Compliance - The company emphasizes the importance of managing accounts receivable, aiming to reduce overdue accounts and improve cash flow efficiency by 2025[125]. - The company has established a management team led by the CFO to ensure timely reconciliation and collection of accounts receivable, with a focus on minimizing bad debt risks[125]. - The company is committed to enhancing its governance structure and ensuring compliance with legal requirements, maintaining a transparent operation[131]. - The company has a robust governance structure that aligns with legal and regulatory requirements, with no significant discrepancies noted[135]. - The company has established a clear framework for internal control, with no significant deficiencies reported[200]. Shareholder Engagement - The company has held five shareholder meetings during the reporting period, ensuring equal treatment of all shareholders[132]. - The participation rates for the extraordinary general meetings indicate a consistent level of shareholder engagement throughout the year[139]. - The company has received recognition and support from investors for its proactive communication regarding its development and financial health[135]. Market Trends and Industry Outlook - The contribution of consumption to economic growth increased to 44.5%, indicating a positive trend for the pharmaceutical and healthcare industry[30]. - The government has implemented policies to enhance compliance in the pharmaceutical sector, which is expected to support the industry's healthy development[31]. - The national pharmaceutical distribution market sales scale reached CNY 2.9304 trillion, with a year-on-year growth of 7.5% after excluding non-comparable factors[35]. Employee and Operational Insights - The total number of employees at the end of the reporting period was 8,264, with 3,732 in sales and 571 in production[180][181]. - The company has implemented a stock incentive plan, granting 13,146,000 shares of restricted stock to 264 incentive targets[188]. - The company has actively organized employee training programs to enhance overall employee quality and efficiency[183]. Financial Management - The company is actively optimizing its capital structure and improving fund management to enhance the efficiency and effectiveness of capital usage[124]. - The company has established a financial sharing system with 96 subsidiaries online by the end of the reporting period, enhancing financial digital transformation[68]. - The company has implemented a performance bonus scheme for senior management based on operational performance and KPI assessments[166].

证券代码：000078 证券简称：海王生物 公告编号：2025-029 本次会计政策变更是公司根据中华人民共和国财政部（以下简称"财政部"） 相关规定进行的相应变更，不会对上市公司营业收入、净利润、净资产等财务成 果产生重大影响。 深圳市海王生物工程股份有限公司 关于会计政策变更的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 一、会计政策变更的原因以及时间 2023 年 10 月，财政部发布《企业会计准则解释第 17 号》（财会〔2023〕 21 号），规定了"关于流动负债与非流动负债的划分"、"关于供应商融资安 排的披露"、"关于售后租回交易的会计处理"的相关内容，该解释规定自 2024 年 1 月 1 日起施行。2024 年 12 月，财政部发布《企业会计准则解释第 18 号》 （财会〔2024〕24 号），规定对于不属于单项履约义务的保证类质量保证，应 当按照《企业会计准 则第 13 号—或有事项》有关规定，按确定的预计负债金额， 借记"主营业务成本"、"其他业务成本"等科目，贷记"预计负债"科目，该 解释规定自印发之日起施行，允许企 ...

证券代码：000078 证券简称：海王生物 公告编号：2025-026 深圳市海王生物工程股份有限公司 关于2025年度日常关联交易预计的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 释义： 公司、本公司：深圳市海王生物工程股份有限公司及其子公司 海王集团：深圳海王集团股份有限公司及其子公司（含其关联方） 海王星辰：山东海王星辰医药连锁集团股份有限公司及其子公司（含其关联 方） 一、日常关联交易基本情况 （一）关联交易概述 （1）与控股股东之关联方 本公司与本公司控股股东海王集团、关联方海王星辰同为医药类企业，各自 业务类型不同。本公司是一家集医药研发、医药制造、医药商业流通于一体的综 合性医药企业；在医药流通领域公司具有较为完善的业务网络及丰富的医药自产 和代理品种。本公司控股股东海王集团为一家大型集团化医药企业。关联方海王 星辰为国内规模最大的连锁药店之一。 结合目前实际情况，本公司与海王集团、海王星辰本着互惠互利、公平公正 的原则，考虑到海王集团、海王星辰和本公司各自的发展趋势，公司预计 2025 年度与海王集团、海王星辰发生的累计关联交易最高交 ...

致同会计师事务所（特殊普通合伙）（以下简称"致同会计师事务所"）为深 圳市海王生物工程股份有限公司（以下简称"公司"或"海王生物"）2023 年度 内部控制审计机构，对公司出具了带强调事项段无保留意见的《内部控制审计报 告》。公司董事局现就内部控制审计报告带强调事项段的无保留审计意见涉及事 项影响已消除的情况说明如下： 一、带强调事项段无保留意见内部控制审计报告涉及事项的基本情况 致同会计师事务所出具的内部控制审计报告带强调事项段无保留意见具体 内容如下： 深圳市海王生物工程股份有限公司 董事局关于 2023 年度内部控制审计报告带强调事项段无保留意 见涉及事项影响已消除的专项说明 为消除上述事项造成的影响，公司本着实事求是的原则，严格按照法律、法 规、规范性文件、《公司章程》及公司相关制度的要求，采取措施消除上述事项 及其影响，采取了以下整改措施： 和信息披露水平，严格规范对外担保事项。 综上所述，公司董事局认为，2023 年度内部控制审计报告带强调事项段的 无保留审计意见涉及事项的影响已经消除。 深圳市海王生物工程股份有限公司 我们提醒内部控制审计报告使用者关注，如《深圳市海王生物股份有限公司 2023 ...

证券代码：000078 证券简称：海王生物 公告编号：2025-023 深圳市海王生物工程股份有限公司 关于公司未弥补亏损超过实收股本总额 三分之一的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市海王生物工程股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开了第九届董事局第二十三次会议、第九届监事会第十九次会议，审议通过 了《关于公司未弥补亏损超过实收股本总额三分之一的议案》，本议案尚需提交 公司 2024 年年度股东大会审议，现将具体内容公告如下： 一、情况概述 根据致同会计师事务所（特殊普通合伙）出具的《2024 年度审计报告》， 公司 2024 年度实现归属于上市公司股东的净利润为-1,193,414,955.25 元，截至 2024 年 12 月 31 日未分配利润为-2,924,031,770.95 元，公司实收股本金额为 2,631,123,257.00 元 （ 公 司 股 份 总 数 为 2,631,123,257.00 股 ， 股 本 金 额 为 2,631,123,257.00 元），未弥补亏损金额超过实收股 ...

证券代码：000078 证券简称：海王生物 公告编号：2025-027 （一）关联方海王集团的基本情况 1、基础信息 深圳市海王生物工程股份有限公司 关于关联方向公司提供借款暨关联交易的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、关联交易概述 为支持公司的发展，提高资金周转效率，公司控股股东深圳海王集团股份有 限公司（以下简称"海王集团"）及其下属子公司预计 2025 年度-2026 年度向深圳 市海王生物工程股份有限公司（以下简称"公司、本公司"）提供累计余额不超 过人民币 10 亿元的借款。借款用于公司日常资金周转和经营，借款利率不高于 公司同期非金融机构借款平均利率。具体借款期限、利率由双方根据实际经营及 海王集团及其下属子公司的资金状况协商确定。公司可根据流动资金需要分批借 款，并可在规定的额度内循环使用该借款。 为支持公司及各区域集团子公司的发展，公司实际控制人及其控制的企业、 其他关联人预计 2025 年度-2026 年度向公司及下属子公司提供累计余额不超过 人民币 5 亿元的借款。借款用于公司及下属子公司日常资金周转，具体借款期限、 ...

深圳市海王生物工程股份有限公司 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》《深圳市海王生物工程股份有限公司独立 董事工作制度》等相关规定，公司董事局就公司现任独立董事张华先生、王焕军 先生、张巍松先生的独立性情况进行评估并出具如下专项意见： 经核查公司现任独立董事张华先生、王焕军先生、张巍松先生的任职经历以 及签署的相关自查文件，公司董事局认为三位独立董事在 2024 年度任职期间恪 尽职守，忠实履职，独立董事本人未在公司担任除独立董事以外的任何职务；独 立董事本人及主要亲属均不属于公司主要股东，均未在公司主要股东及其附属单 位担任任何职务；不属于与本公司及控股股东、实际控制人或其附属企业有重大 业务往来的人员；不属于为本公司及控股股东、实际控制人或其附属单位提供财 务、法律、咨询、保荐等服务的人员；与本公司以及主要股东及其附属企业之间 不存在利害关系或其他可能妨碍其进行独立客观判断的关系；不存在其他影响独 立董事独立性的情况。公司独立董事符合《上市公司独立董事管理办法》《深圳 证券交易所上市公司自律监管指引第 ...